Business Wire via NewsEdge : ** NOTE: TRUNCATED STORY **
Business Editors
NEW YORK--(BUSINESS WIRE)--November 18, 2008--Reportlinker.com announces that a new market research report related to the Pharmaceutical industry industry is available in its catalogue.
World Pharmaceuticals Market Brief
http://www.reportlinker.com/p097881/World-Pharmaceuticals-Market-Brief.html
The global outlook series on Pharmaceuticals provides a collection of statistical anecdotes, market briefs, and concise summaries of research findings. The report provides a bird's eye view of the pharmaceutical industry, and highlights global trends impacting the marketplace, such as, patent expiry of blockbuster global drugs, rising demand for old age related medications and cardiovascular drugs, and the rise of biogenerics, among others. A briefly summarized outlook presents unequivocal views on the industry's future. Punctuated with 18 statistically rich tables, the global market discussion offers special preludes to major market segments, such as, Prescription Drugs, Blockbuster Drugs, Anti-Depressants, COPD, Cholesterol Drugs, CNS Drugs, Cardiovascular Drugs, Cancer Drugs, Attention Deficit Hyperactive Disorder, Artherosclerosis, Asthma, Anti-Infective Prescription Agents, Receptor Blockers, Psychotic Disorders, Osteoporosis, Multiple Sclerosis, Irritable Bowel Syndrome, Insomnia, Immunosupression Hypertension, Epilepsy, Rhinitis, Urinary Disorders, HIV/AIDS, and Diabetes among others. Also included is a recapitulation of recent mergers, acquisitions, and other noteworthy strategic corporate developments. Annotated with quantitative analysis and research findings, the discussion on the US market contains 46 market data tables designed to give the reader a macro level understanding of the market. Other regional markets covered include Canada, Japan, Western Europe, Switzerland, UK, China, India, Korea, Malaysia, and Brazil. The purpose of the abstracted regional market discussion is to provide the reader an introduction to these markets. Also included is an indexed, easy-to-refer, fact-finder directory listing the addresses, and contact details of 3,083 companies worldwide.
PHARMACEUTICALS GOS-041 A GLOBAL OUTLOOK, SEPTEMBER 2008
CONTENTS
1. Overview 1
Table 1: Global Pharmaceutical Market (2006): Sales in US$ Billion by Region - US, Europe, Japan, Asia-Pacific, Latin America, Middle East/Africa and Canada 1 US Leads the Pharmaceuticals Sector 1 Global Trends in Pharmaceutical Industry 1 Aging World Population Drives Up Demand for Pharmaceuticals 1 Market Booming for Old Age Related Medications 2 BRIC Countries to Drive Up the Pharmaceuticals Sector 2 China and India Emerge as Major Contract Manufacturing Hubs 2 Rising Consumer Health Consciousness Drives Up the OTC Drugs Sector 2 Market Growing for OTC Scar Management Solutions 3 Market Growing for Artificial Tears 3 Faster Drug Approval Process, the Need of the Hour 3 Cardiovascular Drugs Still Rules the Roost 3 Global Analgesics Market to Soar 3 Market Growing for Antidepressants 4 New R&D Initiatives To Spark Up Growth 4 Acquisitions and Mergers Propels the Pharmaceuticals Sector 5 Generics Expand Share 5
Table 2: Increasing Share of Generics in the Global Pharmaceutical Market: 1995-2006 (In %) 6
Table 3: Global Generic Drugs Market by Geographic Region: Annual Sales Estimates in US$ Million for 2003 through 2008 for USA, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World 6
Table 4: Global Generic Drugs Market (2005 & 2006): Percentage Breakdown of Value Sales by Therapeutic Category - Cardiovascular, Anti-Infective, Analgesic, Central Nervous System (CNS), Gastrointestinal, Cancer, Respiratory & Anti-Allergic, and Others 7 Global Patent Expiries of Select Major Drugs: 2007-2012 7 Major Generic Drugs 8
Table 5: Leading Generic Drugs Worldwide by Retail Sales (2005): Hydrocodone/APAP, Gabapentin, Amoxicillin/pot. clav., Paroxetine, Oxycodone, Lisinopril, Metformin, Omeprazole, Fentanyl transdermal, Amoxicillin, Fluoxetine, Oxycodone w/ APAP, Albuterol aerosol, Lovastatin, Levothyroxine, Lorazepam, Atenolol, Alprazolam, Cephalexin, and Warfarin 8
Table 6: Leading Generic Drugs Worldwide by Total Units Dispensed (2005): Annual Estimates in Millions for Hydrocodone/APAP, Amoxicillin, Peg 3350/electrolyte, Metformin, Alprazolam, Lisinopril, Atenolol, Hydrochlorothiazide, Furosemide Oral, Chlorhexidine Gluconate, Gabapentin, Ibuprofen, Levothyroxine, Metoprololtartrate, Albuterol nebulizer solution, Propoxyphene-N/APAP, Potassium chloride, Cephalexin, Amoxicillin/pot. Clav., and Tramadol 9 Leading Generic Drug Companies 10
Table 7: Leading Companies in the Global Generic Drugs Market (2005): Percentage Breakdown by Value Sales for Sandoz, Teva Pharmaceutical Industries, Merck Generics, Actavis, Ratiopharm, Mylan Laboratories, IVAX, Barr Pharmaceuticals, Ranbaxy Laboratories, and Others 10
Table 8: Leading Companies in the Global Generics Pharmaceutical Market by Number of Prescriptions Dispensed (2005): Annual Estimates in Millions for Teva/Ivax, Mylan, Sandoz, Watson, Mallinckrodt, Alpharma, Qualitest, Par, Barr, Laboratories, and URL/Mutual 10 Generic Competition Provides the Necessary Momentum 11 Authorized Generics - A Major Concern for Generic Makers 11 Regulatory Reform Drive the European Market 11 New Areas of Expertise 11 Biogeneric Revolution 11 Bio-generics to Exhibit Slow Start 11 Biogeneric Market Trends Worldwide: 2005-2010 12 Select Global Biotech Drugs Off-Patent: 2001-2006 12 Potentially Key Competitors in the Biogenerics Space: 2005-2010 12 Product Lifecycle Management - The Deciding Factor 13
Table 9: TOP 10 Pharmaceutical Products Worldwide in 2004 13 Packaging Trends 14 Blister Packaging to Record High Growth 14
Table 10: Global Pharmaceutical Packaging Demand by Country: Percentage Market Share for 2005, 2008, and 2010 for Europe, North America, Latin America, and Others 14 Outlook 15 Pharmacogenomics to Substitute Pharma's Business Model 15 Biopharmaceuticals - The Next Generation 15
Table 11: Global Demand for Biopharmaceuticals: Annual Market Estimates for 2004 through 2010 in Millions of Liters 16 Nano-Enabled Drug Discovery Geared to Lead 16 Proteomics - The Current Spotlight 16 Neurodegeneration Treatments Identified in Research 17
Table 12: Leading Companies in the Global Pharmaceutical Market by Healthcare Research and Development (R&D) Spending (2005): Annual Estimates in US$ Million for Pfizer Inc., Johnson & Johnson, GlaxoSmithKline Plc, Sanofi-Aventis Group, Novartis, Roche, Merck & Co., AstraZeneca Plc, Eli Lilly and Co., Wyeth, Bristol-Myers Squibb Co., Amgen Inc., Schering-Plough Corp., Abbott Laboratories, Boehringer Ingelheim GmbH, Takeda Pharmaceutical Co., Daiichi Sankyo Co., Genentech Inc., Schering AG, and Astellas Pharma Inc. 17
2. Major Class of Drugs 18 Antidepressants 18 Antiepileptics 18 Antipsychotics 18 Antirheumatic Non-steroidals 18 Antulcerants 18 Calcium Antagonists 18 Erythropoietins 18 Oral Antibiotics 18 Lipid Regulators 18 Antiarthritics 18 Antihistamines 18 Antihyperlipidemics 18 Oral Antidiabetics 18
3. Geographical Landscape 19
Table 13: Global Pharmaceutical Market by Region/Country (2005): Annual Sales in US$ Billion for United States, Europe, Japan, Asia-Pacific, Latin America, Middle East/Africa, and Canada 19
Table 14: Global Pharmaceutical Market by Region/Country (2005): Percentage Breakdown of Value Sales for United States, Europe, Japan, Asia Pacific, Latin America, Middle East/Africa, and Canada 19 Leading Global Pharmaceutical Players 19
Table 15: Leading Global Pharmaceutical Companies by Revenue (2006): Annual Estimates in US$ Billion for Pfizer, GlaxoSmithKline, Novartis, Sanofi-Aventis, Johnson & Johnson, AstraZeneca, Merck, Roche, Abbott, and Amgen 20
Table 16: Leading Global Pharmaceutical Companies by Net Income (2005): Annual Estimates in US$ Million for Johnson & Johnson, GlaxoSmithKline Plc, Procter & Gamble Co., Pfizer Inc., Novartis, Roche, AstraZeneca Plc., Merck & Co., Amgen Inc., Wyeth, Abbott Laboratories, Bristol-Myers Squibb Co., Sanofi-Aventis Group, Takeda Pharmaceutical Co., and Bayer 20
Table 17: Leading Global Pharmaceutical Companies by Market Capitalization (2006): Annual Estimates in US$ Million for Pfizer Inc., Procter & Gamble Co., Johnson & Johnson, GlaxoSmithKline Plc., Novartis, Sanofi-Aventis Group, AstraZeneca Plc, Merck & Co., Genentech Inc., Amgen Inc., Abbott Laboratories, Wyeth, Eli Lilly and Co., Bristol-Myers Squibb Co., and Bayer 21
Table 18: Leading Global Pharmaceutical Companies by Shareholders' Equity (2005): Annual Estimates in US$ Million for Pfizer Inc., Procter & Gamble Co., Sanofi- Aventis Group, Johnson & Johnson, Roche, Novartis, Amgen Inc., Takeda Pharmaceutical Co, Merck & Co., Abbott Laboratories, Bayer, AstraZeneca Plc., GlaxoSmithKline Plc., Wyeth, and Bristol-Myers Squibb Co. 21
Table 19: Leading Global Pharmaceutical Companies by Aggregate Assets (2005): Annual Estimates in US$ Million for Procter & Gamble Co., Pfizer Inc., Sanofi-Aventis Group, Johnson & Johnson, Novartis, Roche, GlaxoSmithKline Plc., Bayer, Merck & Co., Wyeth, Amgen Inc., Abbott Laboratories, Bristol-Myers Squibb Co., Takeda Pharmaceutical Co., and AstraZeneca Plc 22
Table 20: Leading Global Pharmaceutical Companies by Number of US-dispensed Prescriptions (2005): Annual Estimates in Millions for Pfizer, Novartis, Teva, Mylan Laboratories, Watson, GlaxoSmithKline, Merck & Company, Ivax Corporation, AstraZeneca, Mallinckrodt, Johnson & Johnson, Sanofi-Aventis, Barr Laboratories, Abbott Laboratories, and Alpharma USPD 22
Table 21: Leading Global Pharmaceutical Companies by Direct-to-consumer Advertisement Spending (2005): Annual Estimates in US$'000 for GlaxoSmithKline, Pfizer, AstraZeneca, Sanofi-Aventis, Merck & Co., Johnson & Johnson, Novartis, Sepracor, Merck/Schering-Plough Pharmaceuticals, Amgen, Schering-Plough, Allergan, Lilly Icos, Abbott Laboratories, Wyeth, Eli Lilly, Roche, Procter & Gamble, Tap Pharmaceutical Products, and Astellas Pharma 23
4. Mergers and Acquisitions 24
5. Strategic Corporate Developments 76
6. Product Launches 105
7. Review of Select Segments 109 Prescription Drugs 109 Market Overview 109
Table 22: Global Leading Prescription Drug Brand Sales by Category: Annual Market Estimates for 2003 through 2008 in Billions of US$ for Cardiovascular, Hypertension Drugs, Anti-Infective, Psychotherapeutic Agents, Gastrointestinal Therapies, Respiratory Products, and Cholesterol Reduction. 109
Table 23: Global Leading Prescription Drugs Sales by Therapeutic Category (Blood Modifiers): Annual Market Estimation for 2003 through 2008 in Millions of US$ for Anemia, Deep Vein Thrombosis, Hemophilia, Occlusive Arterial Disease, Pulmonary Embolism, Leukopenia, Iron Intoxication, White Blood Cell Enhancement and Peripheral Disease. 110 Blockbuster Drugs 110 Market Overview 110
Table 24: Global Drugs Gaining Blockbuster Status by Sales: Annual Market Estimates for 2003 through 2008 in Billions of US$ for Advair/Seretide, Nexium, Plavix, Singulair, Mabthera/Rituxan, Lovenox/ Clexane, Ambien/Stilnox, Wellbutrin, and Others 111
Table 25: Global Top-Selling Drugs Value Sales: Annual Market Estimates for 2003 through 2008 in Billions of US$ for Chiral, Racemic, and Achiral Drugs 112 Antidepressants 112 Market Overview 112 Leading Antidepressants Worldwide and Year of Patent Expiry 112 Chronic Obstructive Pulmonary Disease 113 Market Overview 113
Table 26: Global Chronic Obstructive Pulmonary Disease Drug Sales by Leading Category: Annual Market Estimates for 2003 through 2008 in Millions of US$ for Beta2-agonists, Anticholinergics, Corticosteroids, Methyl Xanthines and Leukotinene Antagonists 113 Cholesterol Drugs 113 Market Overview 113 Leading Cholesterol Drugs Worldwide and Year of Patent Expiry 114 CNS Drugs 114 Market Overview 114
Table 27: Global Leading Central Nervous System Prescription Drugs Sales by Symptoms: Annual Market Estimates for 2003 through 2008 in Millions of US$ for Depression, Psychotic disorders, Epilepsy, Migraine, Insomnia, Anesthesia, Anxiety, Alzheimer disease, Attention deficit hyperactivity disorder, and Dystonia 114 Cardiovascular Drugs 115 Market Overview 115 Leading Cardiovascular Prescription Drugs 115 Cancer Drugs 115 Market Overview 115 Attention Deficit Hyperactive Disorder 115 Market Overview 115 Artherosclerosis 115 Market Overview 115 Asthma 115 Market Overview 115 Leading Brands 116 Asthma Drug Sales by Respiratory Category 116
Table 28: Global Asthma Drug Value Sales by Respiratory Category: Annual Market Estimates for 2003 through 2008 in Millions of US$ for Inhaled Corticosteroids, Short Acting Beta Agonists, Long Acting Beta Agonists, Combinations, Anti-Leukotrienes and Other Asthma Therapeutics 116 Antinfective Prescription Agents 116 Market Overview 116
Table 29: Global Leading AntInfective Prescription Agents Sales for Various Symptoms: Annual Market Estimates for 2003 through 2008 in Millions of US$ for Bacterial Infections, Viral Infections and Fungal Infections 117 Receptor Blockers 117 Market Overview 117
Table 30: Receptor Blockers Value Sales in the Global Market: Annual Market Estimates for 2003 through 2008 in Billions of US$ 117 Psychotic Disorders 118 Market Overview 118 Worldwide Leading Prescription Drugs for Psychotic Disorders and Year of Patent Expiry 118 Osteoporosis 118 Market Overview 118 Multiple Sclerosis 118 Market Overview 118
Table 31: Global Sales of Leading Prescription Drugs for Multiple Sclerosis in Millions of US$:) 2005 119
Table 32: Global Leading Prescription Drug Sales for Multiple Sclerosis: Annual Market Estimates for 2003 through 2008 in Millions of US$ 119 Irritable Bowel Syndrome 119 Market Overview 119
Table 33: Global Leading Drug Value Sales by Category for Treating Irritable Bowel Syndrome: Annual Market Estimates for 2003 through 2008 in Millions of US$ for Laxatives, Antidiarrheals, and Antidepressants 120
** NOTE: This story has been truncated from its original size in order to facilitate transmission. If you need more information about this story, please contact NewsEdge at 1-973-422-0800 or support@acquiremedia.com. **
<<Business Wire -- 11/19/08>>
<< Copyright ©2008 Business Wire >>
